PT  - JOURNAL ARTICLE
AU  - Chiu, I-Min
AU  - Wu, Po-Jung
AU  - Zhang, Huan
AU  - Hughes, J. Weston
AU  - Rogers, Albert J
AU  - Jalilian, Laleh
AU  - Perez, Marco
AU  - Lin, Chun-Hung Richard
AU  - Lee, Chien-Te
AU  - Zou, James
AU  - Ouyang, David
TI  - Serum Potassium Monitoring using AI-enabled Smart Watch Electrocardiograms
AID  - 10.1101/2024.05.08.24307064
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.08.24307064
4099  - http://medrxiv.org/content/early/2024/05/09/2024.05.08.24307064.short
4100  - http://medrxiv.org/content/early/2024/05/09/2024.05.08.24307064.full
AB  - Background Hyperkalemia poses a significant risk of sudden cardiac death, especially for those with end-stage renal diseases (ESRD). Smartwatches with ECG capabilities offer a promising solution for continuous, non-invasive monitoring using AI.Objectives To develop an AI-ECG algorithm to predict serum potassium level in ESRD patient with smartwatch generated ECG waveforms.Methods A cohort of 152,508 patients with 293,557 ECGs paired serum potassium levels obtained within one hour at Cedars Sinai Medical Center (CSMC) was used to train an AI-ECG model (‘Kardio-Net’) to predict serum potassium level. The model was further fine-tuned on 4,337 ECGs from 1,463 patients with ESRD using inputs from 12-lead and single-lead ECGs. Kardio-Net was evaluated in held-out test cohorts from CSMC and Stanford Healthcare (SHC) as well as a prospective international cohort of 40 ESRD patients with smartwatch ECGs at Chang Gung Memorial Hospital (CGMH).Results The Kardio-Net, when applied to 12-lead ECGs, identified severe hyperkalemia with an AUC of 0.852 and a mean absolute error (MAE) of 0.527 mEq/L. In external validation at SHC, the model achieved an AUC of 0.849 and an MAE of 0.599 mEq/L. For single-lead ECGs, Kardio-Net detected hyperkalemia with an AUC of 0.876 and had an MAE of 0.575 mEq/L in the CSMC test cohort. Using prospectively obtained smartwatch data, the AUC was 0.831, with an MAE of 0.580 mEq/L.Conclusions We validate a deep learning model to predict serum potassium levels from both 12-lead ECGs and single-lead smartwatch data, demonstrating its utility for remote monitoring of hyperkalemia.Condensed Abstract Hyperkalemia significantly increases the risk of sudden cardiac death in end-stage renal disease (ESRD) patients. We developed ‘Kardio-Net,’ an AI-driven ECG model, using data from 152,508 patients at Cedars Sinai Medical Center, and refined it with ECGs from 1,463 ESRD patients using inputs from 12-lead and single-lead ECGs. This model facilitates continuous and non-invasive potassium monitoring, leveraging both traditional and smartwatch-generated ECGs. Tested across various cohorts, including a prospective smartwatch group, Kardio-Net achieved an AUC range of 0.807 to 0.876, demonstrating its effectiveness for real-time hyperkalemia monitoring.Competing Interest StatementThe authors have declared no competing interest.Funding StatementI.M.C receive funding from National Science and Technology Council in Taiwan (111-2221-E-182A-008-); D.O and I.M.C receive funding from Apple and the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review boards of the Cedars-Sinai Medical Center, Standford Healthcare, and Chang Gung Memorial Hospital.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are not publicly available due to restrictions.ESRDEnd-Stage Renal DiseaseECGElectrocardiogramAIArtificial IntelligenceDLDeep LearningSHCStanford HealthCareCGMHChang Gung Memorial HospitalCNNConvolutional Neural NetworkAUCArea Under the receiver operating characteristic CurveMAEMean Absolute ErrorIQRInterquartile Range